SYCE1L-1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: SYCE1L

NCBI ID: G100130958

SYCE1L

SYCE1L-1: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent and often severe pain can have a significant impact on an individual's quality of life, and can even lead to disability and malnutrition. The underlying mechanisms of chronic pain are complex, and its treatment often involves a combination of medications, lifestyle modifications, and physical therapy. However, there is a growing need for more effective and targeted treatments to manage this chronic suffering.

SYCE1L-1: A Potential Drug Target

SYCE1L-1 (secretin-like protein-1-like) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It has been shown to play a role in the regulation of pain perception and persistence. Synaptic plasticity, the ability of neural connections to change and adapt, is a key mechanism that allows the brain to learn and adapt to new experiences. SYCE1L-1 has been shown to regulate the release of neurotransmitters, such as dopamine and opioids, which are involved in pain modulation.

SYCE1L-1 has also been shown to interact with other proteins involved in pain signaling, including TrkB, a G protein-coupled receptor that is involved in pain perception. TheTrkB receptor is a target for several approved pain medications, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). The interactions between SYCE1L-1 and TrkB suggest that SYCE1L-1 may be a potential drug target for chronic pain.

SYCE1L-1 as a Biomarker

One of the challenges in the treatment of chronic pain is the difficulty in identifying the underlying causes of the pain. The symptoms of chronic pain can be similar, and the underlying mechanisms may not be immediately apparent. In this case, SYCE1L-1 may serve as a biomarker, a protein that can be used as a diagnostic tool to identify the underlying causes of chronic pain.

SYCE1L-1 has been shown to be expressed in various tissues and cells involved in pain signaling, including the brain, pancreas, and gastrointestinal tract. It is also involved in the regulation of pain perception and persistence. The expression of SYCE1L-1 has been shown to be affected by various factors, including pain modulation, neurotransmitter release, and cellular signaling pathways.

In addition, SYCE1L-1 has been shown to interact with other proteins involved in pain signaling, including TrkB. The interactions between SYCE1L-1 and TrkB suggest that SYCE1L-1 may be a potential drug target for chronic pain, and that it may be able to serve as a biomarker for identifying the underlying causes of chronic pain.

Conclusion

SYCE1L-1 is a protein that has been shown to play a role in the regulation of pain perception and persistence. Its interaction with TrkB and other proteins involved in pain signaling suggests that it may be a potential drug target for chronic pain. As a biomarker, SYCE1L-1 may be able to identify the underlying causes of chronic pain and guide the development of more effective and targeted treatments. Further research is needed to fully understand the role of SYCE1L-1 in pain management and to develop effective treatments.

Protein Name: Synaptonemal Complex Central Element Protein 1 Like

Functions: May be involved in meiosis

The "SYCE1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYCE1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets